Stretched Tissue Mounting for MALDI Mass Spectrometry Imaging

Department of Chemistry and the Beckman Institute, University of Illinois, Urbana, Illinois 61801, USA.
Analytical Chemistry (Impact Factor: 5.83). 12/2011; 83(23):9181-5. DOI: 10.1021/ac201857k
Source: PubMed

ABSTRACT Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) combines information-rich chemical detection with spatial localization of analytes. For a given instrumental platform and analyte class, the data acquired can represent a compromise between analyte extraction and spatial information. Here, we introduce an improvement to the spatial resolution achievable with MALDI MSI conducted with standard mass spectrometric systems that also reduces analyte migration during matrix application. Tissue is placed directly on a stretchable membrane that, when stretched, fragments the tissue into micrometer-sized pieces. Scanning electron microscopy analysis shows that this process produces fairly homogeneous distributions of small tissue fragments separated and surrounded by areas of hydrophobic membrane surface. MALDI matrix is then applied by either a robotic microspotter or an artist's airbrush. Rat spinal cord samples imaged with an instrumental resolution of 50-250 μm demonstrate lipid distributions with a 5-fold high spatial resolution (a 25-fold increase in pixel density) after stretching compared to tissues that were not stretched.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Single cell analysis is an emerging field requiring a high level interdisciplinary collaboration to provide detailed insights into the complex organisation, function and heterogeneity of life. This review is addressed to life science researchers as well as researchers developing novel technologies. It covers all aspects of the characterisation of single cells (with a special focus on mammalian cells) from morphology to genetics and different omics-techniques to physiological, mechanical and electrical methods. In recent years, tremendous advances have been achieved in all fields of single cell analysis: (1) improved spatial and temporal resolution of imaging techniques to enable the tracking of single molecule dynamics within single cells; (2) increased throughput to reveal unexpected heterogeneity between different individual cells raising the question what characterizes a cell type and what is just natural biological variation; and (3) emerging multimodal approaches trying to bring together information from complementary techniques paving the way for a deeper understanding of the complexity of biological processes. This review also covers the first successful translations of single cell analysis methods to diagnostic applications in the field of tumour research (especially circulating tumour cells), regenerative medicine, drug discovery and immunology.
    The Analyst 02/2014; DOI:10.1039/c3an01939j · 3.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mass spectrometry imaging (MSI) has gone through a significant change over the last three years, the time span of this review. The predominant mass spectrometric method in biomolecular imaging has been matrix-assisted laser desorption/ionization (MALDI). MALDI MSI, after its first introduction in 1994 [1] has suffered from a phase of rather unsystematic use, without validation on an analytical-science level. Not meeting a high standard of validity for these colorful pictures, MSI reached a dangerous state of being suspected as a non-trustful method, useless for precise biomedical or molecular-biological research. With the introduction of new, highly sensitive, highly accurate methods of data acquisition and imaging, which were based on high mass resolution, high mass accuracy and high lateral resolution, MALDI MSI recovered and developed as a powerful, versatile and valid method in bioanalytical sciences [2-4]. At the same time alternative ionization methods came into the game, providing imaging capability with reduced sample preparation requirements and specific analytical properties. The last three years have thus been characterized by developments and applications in biomolecular imaging, which are unprecedented not only in the view of mass spectrometrists.
    Analytical Chemistry 12/2014; 87(1). DOI:10.1021/ac504543v · 5.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The common human neurodegenerative disorders such as Amyotrophic lateral sclerosis (ALS), Alzheimer's (AD) and Parkinson's diseases (PD) are a heterogeneous group of neurologic disorders that are characterized by the progressive loss of brain function. In ALS, selective and relentless degeneration occurs in both upper and lower motor neurons, resulting in mortality usually within 5 years of symptom onset. However, surviving rates vary among individual patients that can be from a few months to >10 years. Inadequacy in disease detection, treatment as well as lack of diagnostic and prognostic tools have prompted many to turn to proteomics-based biomarker discovery efforts. Proteomics refer to the study of the proteins expressed by a genome at a particular time in a whole cell or a tissue etc. and the proteome can respond to and reflects the status of an organism including health and disease states. Although an emerging field proteomics application promise to uncover biomarkers critical for differentiating patients with neurodegenerative diseases from healthy people and from patients affected by other diseases. These studies will also contribute mechanistic information to facilitate identification of new drug targets for subsequent therapeutic development. In addition to proper experimental conception, standard operating technique for sample procurement, pre-processing, and storage must be developed. Biological samples generally analyzed in proteomic studies of neurologic diseases include both plasma and cerebro spinal fluid. Recent studies have identified individual protein or protein panels from blood plasma and CSF that represent putative biomarkers for neurodegenerative diseases like AD and ALS, although many of these proteins are not unique to this disease. Continued research investigations are required to validate these initial findings and to further pursue the role of these proteins as diagnostic biomarkers or surrogate markers of disease progression. Protein biomarkers specific to amyotrophic lateral sclerosis (ALS) will additionally function to evaluate drug efficacy in clinical trials and to identify novel targets for drug design. It is hoped that proteomic based technologies will soon integrate the basic biology of neurologic disorders with mechanistic disease information to achieve success in the clinical setting.

Full-text (2 Sources)

Available from
May 16, 2014